Medicenna Therapeutics Corp. MDNA.TO
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX · Canada · medicenna.com
Medicenna Therapeutics Corp. is a clinical-stage biopharmaceutical company developing IL-2, IL-4, and IL-13 Superkines and bi-functional Superkines for the treatment of cancer and autoimmune diseases. The company's lead program, MDNA55, is an IL-4 receptor-targeted immunotherapy in clinical development for recurrent glioblastoma multiforme. Medicenna is headquartered in Toronto, Ontario.
Key ratios
ReturnOnAssets TTM -0.62
ReturnOnAssets 2025 -0.54
ReturnOnAssets 2024 -0.42
ReturnOnAssets 2023 -0.34
ReturnOnEquity TTM -1.1
ReturnOnEquity 2025 -0.97
ReturnOnEquity 2024 -1.47
ReturnOnEquity 2023 -0.4
Recent news
Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights
2026-06-26 · GlobeNewswire